Establishment Labs (NASDAQ:ESTA) Reaches New 52-Week High – Should You Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) reached a new 52-week high on Thursday . The company traded as high as $86.00 and last traded at $85.2260, with a volume of 59029 shares traded. The stock had previously closed at $82.39.

Analyst Ratings Changes

A number of research firms have weighed in on ESTA. BTIG Research boosted their price objective on Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a research note on Wednesday, May 6th. Wall Street Zen lowered Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Finally, Stephens boosted their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus target price of $87.14.

Establishment Labs Trading Up 2.3%

The company has a fifty day simple moving average of $70.25 and a two-hundred day simple moving average of $69.48. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The company has a market cap of $2.48 billion, a PE ratio of -56.60 and a beta of 1.11.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The company had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. During the same quarter last year, the company earned ($0.70) EPS. Establishment Labs’s revenue for the quarter was up 44.7% compared to the same quarter last year. Analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Insiders Place Their Bets

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the sale, the director owned 927,504 shares in the company, valued at $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last quarter, insiders sold 330,000 shares of company stock worth $22,854,538. 9.99% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Establishment Labs

Several large investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC increased its holdings in Establishment Labs by 11.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock worth $80,893,000 after purchasing an additional 197,962 shares during the period. Bamco Inc. NY increased its holdings in Establishment Labs by 30.2% during the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock worth $48,443,000 after purchasing an additional 274,287 shares during the period. Tyro Capital Management LLC boosted its position in shares of Establishment Labs by 1.0% during the 3rd quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock worth $44,165,000 after acquiring an additional 10,735 shares in the last quarter. William Blair Investment Management LLC boosted its position in shares of Establishment Labs by 17.6% during the 3rd quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock worth $41,709,000 after acquiring an additional 152,299 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Establishment Labs by 117.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after acquiring an additional 438,206 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.